Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared on LinkedIn:
“Kicking off 2026: A New Perspective on Avatrombopag in Aplastic Anemia
I am pleased to start the new year by sharing our latest review article, published in Therapeutic Advances in Hematology.
While Thrombopoietin Receptor Agonists (TPO-RAs) like Eltrombopag have revolutionized the treatment of Aplastic Anemia (AA), hepatotoxicity and dietary restrictions remain significant challenges for many patients.
Our team conducted a comprehensive review of clinical evidence from 2023 to 2025 to evaluate the efficacy and safety of Avatrombopag (AVA) as an alternative.
Key Findings for Clinical Practice:
- High Efficacy: Across the reviewed studies, we observed Overall Response Rates (ORR) ranging from 55% to 85%, with complete response rates reaching up to one-third of treated patients.
- Superior Liver Safety: Unlike earlier agents in this class, Avatrombopag demonstrated a favorable safety profile with no clinically relevant hepatotoxicity reported. It appears safe even for patients with underlying liver dysfunction.
- Rapid Response: Hematologic improvement typically occurred within 1–2 months, aligning well with clinical decision-making timelines.
- Patient Convenience: AVA requires no dietary restrictions and does not undergo significant hepatic metabolism, simplifying management for complex patients.
Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence
I extend my sincere gratitude to Dr. Mostafa Faisal Mohammed Saleh, Dr. Ahmed Kotb Abdrabou, Dr. Alfadil Haroon, Dr. Hadeel Samarkandi, Dr. Hazza Alzahrani, Dr. Mahmoud Aljurf, Dr. Ali Alahmari.
Read the full review here.”
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal